Eagle Pharmaceuticals, Inc.
EGRX
$1.90
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -12.80% | -42.78% | 43.43% | 65.36% | 54.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.80% | -42.78% | 43.43% | 65.36% | 54.05% |
| Cost of Revenue | -28.76% | -37.67% | 61.39% | 186.37% | 119.99% |
| Gross Profit | -5.32% | -44.39% | 36.06% | 33.73% | 35.07% |
| SG&A Expenses | 43.03% | 26.05% | 24.23% | 17.75% | 16.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.17% | -2.70% | 43.69% | 9.41% | 45.92% |
| Operating Income | -47.70% | -80.32% | 41.82% | 209.68% | 82.10% |
| Income Before Tax | 258.45% | -82.26% | 986.93% | 71.07% | -205.77% |
| Income Tax Expenses | 15.41% | -67.06% | -30.74% | 149.28% | 85.02% |
| Earnings from Continuing Operations | 154.65% | -86.95% | 231.78% | -26.84% | -361.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 154.65% | -86.95% | 231.78% | -26.84% | -361.63% |
| EBIT | -47.70% | -80.32% | 41.82% | 209.68% | 82.10% |
| EBITDA | -25.56% | -71.46% | 100.92% | 261.89% | 82.15% |
| EPS Basic | 153.59% | -87.30% | 230.58% | -25.98% | -367.22% |
| Normalized Basic EPS | -27.66% | -82.81% | 197.25% | 121.23% | 17.19% |
| EPS Diluted | 152.70% | -87.10% | 228.96% | -25.95% | -374.07% |
| Normalized Diluted EPS | -28.01% | -82.66% | 194.81% | 121.23% | 18.56% |
| Average Basic Shares Outstanding | 1.99% | 2.74% | 0.93% | 0.69% | -2.08% |
| Average Diluted Shares Outstanding | 2.48% | 1.91% | 1.77% | 0.69% | -3.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |